Toggle light / dark theme

Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson’s disease

After transplantation into the brain of patients with Parkinson’s disease, allogeneic dopaminergic progenitors derived from induced pluripotent stem cells survived, produced dopamine and did not form tumours, therefore suggesting safety and potential clinical benefits for Parkinson’s disease.

Leave a Comment

Lifeboat Foundation respects your privacy! Your email address will not be published.

/* */